49
Participants
Start Date
June 29, 2004
Primary Completion Date
February 12, 2021
Study Completion Date
February 12, 2021
Fludarabine
25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
Mitoxantrone
10 mg/m\^2 IV over 5-30 minutes on Day 2.
Rituximab
375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
Zevalin
0.3 mCi/kg IV after 4 cycles of R-FND.
Dexamethasone
20 mg by mouth (PO) or IV daily on Days 2-6.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (2)
Genentech, Inc.
INDUSTRY
Biogen
INDUSTRY
M.D. Anderson Cancer Center
OTHER